Literature DB >> 29127844

The role of A-to-I RNA editing in cancer development.

Xiaoyan Xu1, Yumeng Wang2, Han Liang3.   

Abstract

Adenosine-to-inosine (A-to-I) RNA editing is the most common type of post-transcriptional nucleotide modification in humans, which is catalyzed in ADAR enzymes. Recent genomic studies have revealed thousands of altered RNA editing events in various cancer tissues, leading to diverse functional consequences. A critical role of individual A-to-I RNA editing events in cancer has been reported. Here, we review the current state of our knowledge on key A-to-I RNA editing events in coding and non-coding regions for their roles in cancer development and discuss their potential clinical utility. A better understanding of A-to-I RNA editing and its oncogenic mechanisms may facilitate the development of novel cancer therapeutic strategies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29127844      PMCID: PMC5869101          DOI: 10.1016/j.gde.2017.10.009

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  38 in total

1.  A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains.

Authors:  C X Chen; D S Cho; Q Wang; F Lai; K C Carter; K Nishikura
Journal:  RNA       Date:  2000-05       Impact factor: 4.942

2.  A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.

Authors:  Masataka Nakano; Tatsuki Fukami; Saki Gotoh; Miki Nakajima
Journal:  J Biol Chem       Date:  2017-02-10       Impact factor: 5.157

Review 3.  Current progress of siRNA/shRNA therapeutics in clinical trials.

Authors:  John C Burnett; John J Rossi; Katrin Tiemann
Journal:  Biotechnol J       Date:  2011-07-11       Impact factor: 4.677

4.  Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.

Authors:  Leilei Chen; Yan Li; Chi Ho Lin; Tim Hon Man Chan; Raymond Kwok Kei Chow; Yangyang Song; Ming Liu; Yun-Fei Yuan; Li Fu; Kar Lok Kong; Lihua Qi; Yan Li; Na Zhang; Amy Hin Yan Tong; Dora Lai-Wan Kwong; Kwan Man; Chung Mau Lo; Si Lok; Daniel G Tenen; Xin-Yuan Guan
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

Review 5.  Functions and regulation of RNA editing by ADAR deaminases.

Authors:  Kazuko Nishikura
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

6.  ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.

Authors:  Maria Anna Zipeto; Angela C Court; Anil Sadarangani; Nathaniel P Delos Santos; Larisa Balaian; Hye-Jung Chun; Gabriel Pineda; Sheldon R Morris; Cayla N Mason; Ifat Geron; Christian Barrett; Daniel J Goff; Russell Wall; Maurizio Pellecchia; Mark Minden; Kelly A Frazer; Marco A Marra; Leslie A Crews; Qingfei Jiang; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-06-09       Impact factor: 24.633

7.  ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer.

Authors:  Tim Hon Man Chan; Aditi Qamra; Kar Tong Tan; Jing Guo; Henry Yang; Lihua Qi; Jaymie Siqi Lin; Vanessa Hui En Ng; Yangyang Song; Huiqi Hong; Su Ting Tay; Yujing Liu; Jeeyun Lee; Sun Yong Rha; Feng Zhu; Jimmy Bok Yan So; Bin Tean Teh; Khay Guan Yeoh; Steve Rozen; Daniel G Tenen; Patrick Tan; Leilei Chen
Journal:  Gastroenterology       Date:  2016-07-01       Impact factor: 22.682

8.  Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.

Authors:  Einav Shoshan; Aaron K Mobley; Russell R Braeuer; Takafumi Kamiya; Li Huang; Mayra E Vasquez; Ahmad Salameh; Ho Jeong Lee; Sun Jin Kim; Cristina Ivan; Guermarie Velazquez-Torres; Ka Ming Nip; Kelsey Zhu; Denise Brooks; Steven J M Jones; Inanc Birol; Maribel Mosqueda; Yu-ye Wen; Agda Karina Eterovic; Anil K Sood; Patrick Hwu; Jeffrey E Gershenwald; A Gordon Robertson; George A Calin; Gal Markel; Isaiah J Fidler; Menashe Bar-Eli
Journal:  Nat Cell Biol       Date:  2015-02-16       Impact factor: 28.824

9.  A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.

Authors:  Tim Hon Man Chan; Chi Ho Lin; Lihua Qi; Jing Fei; Yan Li; Kol Jia Yong; Ming Liu; Yangyang Song; Raymond Kwok Kei Chow; Vanessa Hui En Ng; Yun-Fei Yuan; Daniel G Tenen; Xin-Yuan Guan; Leilei Chen
Journal:  Gut       Date:  2013-06-13       Impact factor: 23.059

10.  LNCediting: a database for functional effects of RNA editing in lncRNAs.

Authors:  Jing Gong; Chunjie Liu; Wei Liu; Yu Xiang; Lixia Diao; An-Yuan Guo; Leng Han
Journal:  Nucleic Acids Res       Date:  2016-09-19       Impact factor: 16.971

View more
  22 in total

Review 1.  ADARs, RNA editing and more in hematological malignancies.

Authors:  Phaik Ju Teoh; Mun Yee Koh; Wee Joo Chng
Journal:  Leukemia       Date:  2020-11-02       Impact factor: 11.528

2.  RNA modifications and cancer.

Authors:  Phensinee Haruehanroengra; Ya Ying Zheng; Yubin Zhou; Yun Huang; Jia Sheng
Journal:  RNA Biol       Date:  2020-02-07       Impact factor: 4.652

3.  RNA modification "writer"-mediated RNA modification patterns and tumor microenvironment characteristics of cervical cancer.

Authors:  Yanjun Qu; Hong Zhu; Congcong Kong; Xin Zheng; Dejun Wang; Xiuwei Chen; Dandan Yuan
Journal:  Clin Transl Oncol       Date:  2022-02-27       Impact factor: 3.405

Review 4.  Roles and mechanisms of alternative splicing in cancer - implications for care.

Authors:  Sophie C Bonnal; Irene López-Oreja; Juan Valcárcel
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

Review 5.  Targeting mRNA processing as an anticancer strategy.

Authors:  Joana Desterro; Pedro Bak-Gordon; Maria Carmo-Fonseca
Journal:  Nat Rev Drug Discov       Date:  2019-09-25       Impact factor: 84.694

Review 6.  RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets.

Authors:  Yang Pan; Kathryn E Kadash-Edmondson; Robert Wang; John Phillips; Song Liu; Antoni Ribas; Richard Aplenc; Owen N Witte; Yi Xing
Journal:  Trends Pharmacol Sci       Date:  2021-04       Impact factor: 14.819

7.  Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma.

Authors:  Huajing Teng; Fengbiao Mao; Jialong Liang; Meiying Xue; Wenqing Wei; Xianfeng Li; Kun Zhang; Dongdong Feng; Baoguo Liu; Zhongsheng Sun
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

8.  Identification of neoantigens derived from alternative splicing and RNA modification.

Authors:  Jiyeon Park; Yeun-Jun Chung
Journal:  Genomics Inform       Date:  2019-08-22

9.  A protein-protein interaction underlies the molecular basis for substrate recognition by an adenosine-to-inosine RNA-editing enzyme.

Authors:  Suba Rajendren; Aidan C Manning; Haider Al-Awadi; Kentaro Yamada; Yuichiro Takagi; Heather A Hundley
Journal:  Nucleic Acids Res       Date:  2018-10-12       Impact factor: 16.971

Review 10.  Novel Engineered Programmable Systems for ADAR-Mediated RNA Editing.

Authors:  Guillermo Aquino-Jarquin
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-15       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.